Professor Thomas Oxley MBBS BMedSc FRACP PhD is a vascular and interventional neurologist and world expert in brain computer interfaces. Dr Oxley is the founding CEO of Synchron, a neurotechnology company based in New York City, having raised over US$145M in capital. Synchron is a clinical stage company developing an endovascular implantable brain computer interface, StentrodeTM. The Synchron BCI is a minimally invasive brain implant for people with debilitating medical illnesses designed to restore autonomy by reconnecting them online in ways that can dramatically improve their lives.

He is a Clinical Instructor, Attending in the Department of Neurosurgery, Mount Sinai Hospital, New York City. Dr Oxley has performed over 1600 endovascular neurosurgical procedures, including cerebral aneurysm coiling and clot retrievals in acute stroke. Dr Oxley has published over 120 internationally peer reviewed articles in journals including JAMA Neurology, Nature Biotechnology, Nature Biomedical Engineering, New England Journal of Medicine and The Lancet. He has over 100 patents filed. He is also Professor of Medicine, University of Melbourne, Australia.

In 2023, Dr Oxley and Synchron completed enrollment in an FDA-approved clinical trial on the Stentrode motor neuroprosthesis that is paving the way towards first FDA marketing approval for an implanted brain computer interface, bringing the total number of patients implanted with the system to 10 worldwide.